文献速递头颈与中枢神经肿瘤

FET-PET与增强T1 MRI引导复发胶质母细胞瘤再照射的随机试验

O-(2-[18F]fluoroethyl)-L-tyrosine-PET-guided versus contrast-enhanced T1-weighted MRI-guided re-irradiation in patients with recurrent glioblastoma (GLIAA/NOA-10 ARO2013-01): a multicentre, open-label, randomised trial.
PubMed 文献 · Lancet Oncol · 2025-12-19

GLIAA/NOA-10多中心开放随机试验纳入200例复发胶质母细胞瘤患者,1:1比较FET-PET与CE-T1MRI靶区勾画后行39 Gy/13次再照射。结论:FET-PET未带来显著临床获益,CE-T1MRI仍是首选勾画方法。

要点

  • FET-PET引导再照射未显著改善复发胶质母细胞瘤的无进展生存。
  • 两组放射性坏死等3-4级不良事件发生率相似。
  • CE-T1MRI仍是复发胶质母细胞瘤再照射的首选靶区勾画方法。

核心结论

  • FET-PET-based target volume delineation for re-irradiation did not lead to a significant clinical benefit compared with CE-T1MRI-based treatment in patients with recurrent glioblastoma.
  • CE-T1MRI remains the preferred delineation method in this setting.

研究设计与样本

  • GLIAA was a multicentre, open-label, parallel randomised study done in 15 radiation oncology centres in Germany.
  • Patients aged 18 years or older with a Karnofsky performance score greater than 60% and a macroscopic WHO grade IV recurrent glioblastoma (1-6 cm) were randomly assigned (1:1) to FET-PET-based or CE-T1MRI-based target volume delineation.
  • Randomisation was stratified by time since first radiotherapy, previous chemotherapy, tumour diameter, MGMT status, and planned chemotherapy.
  • The primary endpoint was progression-free survival from randomisation, assessed in the per-protocol population.

主要发现

  • Median progression-free survival was 4·0 months (95% CI 3·7-5·2) in the FET-PET group and 4·9 months (3·7-6·0) in the CE-T1MRI group (one-sided stratified log-rank p=0·98; adjusted hazard ratio 1·14 [95% CI 0·85-1·52]; p=0·39).
  • The most common grade 3-4 adverse event was radionecrosis (eight [8%] of 99 in the FET-PET group vs seven [7%] of 99 in the CE-T1MRI group).
  • Acute and subacute serious adverse events occurred in 15 (15%) of 99 patients in each group.
  • Possibly re-irradiation-related late serious adverse events occurred in ten (10%) of 97 patients in the FET-PET group and 18 (19%) of 96 in the CE-T1MRI group.
  • There were no treatment-related deaths.

关键数值与推荐

  • Re-irradiation was delivered with 39 Gy in 13 fractions.
  • 98 patients in the FET-PET group and 97 in the CE-T1MRI group were treated per protocol.
  • Median follow-up for censored patients was 12·2 months (IQR 6·6-20·7).

临床怎么用

  • For patients with recurrent glioblastoma scheduled for re-irradiation, CE-T1MRI remains the preferred target volume delineation method.
  • FET-PET-based delineation did not show a significant clinical benefit over CE-T1MRI in this setting.

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: O-(2-[18F]fluoroethyl)-L-tyrosine (FET)-PET has a higher specificity than contrast-enhanced T1-weighted MRI (CE-T1MRI) in diagnosing recurrent glioblastoma. We aimed to evaluate whether a FET-PET-based target volume delineation, compared with CE-T1MRI, improves outcomes in patients with recurrent glioblastoma scheduled for re-irradiation. METHODS: GLIAA was a multicentre, open-label, parallel randomised study done in 15 radiation oncology centres in Germany. Patients aged 18 years or older with a Karnofsky performance score greater than 60% and a macroscopic WHO grade IV recurrent glioblastoma (1-6 cm) were randomly assigned (1:1) to receive either FET-PET-based or CE-T1MRI-based target volume delineation followed by re-irradiation with 39 Gy in 13 fractions. Randomisation was performed centrally, using a minimisation technique with a random element and a computer-assisted randomisation tool, stratified by time since first radiotherapy, previous chemotherapy, tumour diameter, MGMT status, and planned chemotherapy. The primary endpoint was progression-free survival from randomisation, assessed in the per-protocol population (patients who initiated treatment per their assigned group). Adverse events were systematically assessed in all patients who commenced therapy. The trial was registered with ClinicalTrials.gov (NCT01252459), German Clinical Trials Registry (DRKS00000634), and European Clinical Trials Database (EudraCT 2012-001121-27), and is completed. FINDINGS: Between Nov 22, 2013, and Aug 18, 2021, 271 patients were recruited and screened for eligibility, 200 of whom were randomly assigned to re-irradiation based on FET-PET (n=100) or CE-T1MRI (n=100). 85 (43%) participants were female and 115 (58%) were male. 98 patients in the FET-PET group and 97 in the CE-T1MRI group were treated per protocol. Median follow-up for censored patients was 12·2 months (IQR 6·6-20·7). Median progression-free survival was 4·0 months (95% CI 3·7-5·2) in the FET-PET group and 4·9 months (3·7-6·0) in the CE-T1MRI group (one-sided stratified log-rank p=0·98; adjusted hazard ratio 1·14 [95% CI 0·85-1·52]; p=0·39; median follow-up for six censored patients 4·1 months [IQR 2·3-6·6]). The most common grade 3-4 adverse event was radionecrosis (eight [8%] of 99 in the FET-PET group vs seven [7%] of 99 in the CE-T1MRI group). Acute and subacute serious adverse events occurred in 15 (15%) of 99 patients in each group; possibly re-irradiation-related late serious adverse events occurred in ten (10%) of 97 patients in the FET-PET group and 18 (19%) of 96 in the CE-T1MRI group. There were no treatment-related deaths. INTERPRETATION: FET-PET-based target volume delineation for re-irradiation did not lead to a significant clinical benefit compared with CE-T1MRI-based treatment in patients with recurrent glioblastoma. Thus, CE-T1MRI remains the preferred delineation method in this setting. FUNDING: Deutsche Krebshilfe.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Grosu AL, Weber WA, Graf E, et al. O-(2-[18F]fluoroethyl)-L-tyrosine-PET-guided versus contrast-enhanced T1-weighted MRI-guided re-irradiation in patients with recurrent glioblastoma (GLIAA/NOA-10 ARO2013-01): a multicentre, open-label, randomised trial. Lancet Oncol. 2025. PMID: 41429128. doi:10.1016/S1470-2045(25)00642-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。